纤维化是50多种不同疾病的共同特征,也是全球35%以上死亡的原因。哪个肝脏,肾,皮肤,心和,最近,肺部受到最多关注。组织变化,导致器官功能丧失,是疾病和结果的原因和结果。纤维化是由细胞外基质蛋白的过度沉积引起的,随着时间的推移会导致器官功能受损和器官衰竭,导致成纤维细胞活化增加的途径有很多。这篇叙述性综述调查了纤维化的共同点,成纤维细胞,和成纤维细胞的激活,为了应对肝脏中过量的能量消耗,肾,心,皮肤和肺纤维化。成纤维细胞是肺器官功能丧失的主要驱动因素,肝脏,皮肤,心脏和肾脏疾病。响应于过量能量消耗的成纤维细胞活化导致一系列胶原蛋白的过度生产,哪些类型的I,III和VI似乎是疾病进展的重要驱动因素。成纤维细胞活化可以在血清中定量,能够对患者进行分析和选择。成纤维细胞的激活导致胶原蛋白的过度生产,使器官功能恶化。患者血清中成纤维细胞活性的分析,量化为胶原蛋白的产生,可以识别器官死亡轨迹,更好地识别用于不同代谢干预的正确治疗方法。由于代谢激活的患者患肾脏的风险很高,肝脏和心脏衰竭,首先确定要治疗哪个器官,并监测器官状态以纠正治疗方案。与此直接对齐,确定正确的患者与正确的器官恶化轨迹,以纳入临床研究是至关重要的。
Fibrosis is a common feature of more than 50 different diseases and the cause of more than 35% of deaths worldwide, of which liver, kidney, skin, heart and, recently, lungs are receiving the most attention. Tissue changes, resulting in loss of organ function, are both a cause and consequence of disease and outcome. Fibrosis is caused by an excess deposition of extracellular matrix proteins, which over time results in impaired organ function and organ failure, and the pathways leading to increased fibroblast activation are many. This narrative review investigated the common denominator of fibrosis, fibroblasts, and the activation of fibroblasts, in response to excess energy consumption in liver, kidney, heart, skin and lung fibrosis. Fibroblasts are the main drivers of organ function loss in lung, liver, skin, heart and kidney disease. Fibroblast activation in response to excess energy consumption results in the overproduction of a range of collagens, of which types I, III and VI seem to be the essential drivers of disease progression. Fibroblast activation may be quantified in serum, enabling profiling and selection of patients. Activation of fibroblasts results in the overproduction of collagens, which deteriorates organ function. Patient profiling of fibroblast activities in serum, quantified as collagen production, may identify an organ death trajectory, better enabling identification of the right treatment for use in different metabolic interventions. As metabolically activated patients have highly elevated risk of kidney, liver and heart failure, it is essential to identify which organ to treat first and monitor organ status to correct treatment regimes. In direct alignment with this, it is essential to identify the right patients with the right organ deterioration trajectory for enrolment in clinical studies.